Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04405076 · ClinicalTrials.gov registry record · Phase 2
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 660
- Enrollment target
NCT04405076 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 660 participants.
The verdict
NCT04405076, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 660 participants
- Enrollment target
Study Summary
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273.351
- BIOLOGICAL Biological: mRNA-1273
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04405076
The ClinicalTrials.gov registry entry for NCT04405076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04405076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04405076 about?
NCT04405076 is a clinical study titled "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older". This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
What is the current status of trial NCT04405076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 660 participants. The study started on 2020-05-29. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT04405076?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273.351 (BIOLOGICAL), Biological: mRNA-1273 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04405076?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.